Asset Details
Do you wish to reserve the book?
Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives
Do you wish to request the book?
Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives
2022
Overview
Metabolism of tryptophan (Trp), an essential amino acid, represent a major metabolic pathway that both promotes tumor cell intrinsic malignant properties as well as restricts antitumour immunity, thus emerging as a drug development target for cancer immunotherapy. Three cytosolic enzymes, namely indoleamine 2,3-dioxygenase 1 (IDO1), IDO2 and tryptophan 2,3-dioxygenase (TDO2), catalyzes the first-rate limiting step of the degradation of Trp to kynurenine (Kyn) and modulates immunity toward immunosuppression mainly through the aryl hydrocarbon receptor (AhR) activation in numerous types of cancer. By restoring antitumor immune responses and synergizing with other immunotherapies, the encouraging preclinical data of IDO1 inhibitors has dramatically failed to translate into clinical success when combined with immune checkpoints inhibitors, reigniting the debate of combinatorial approach. In this review, we i) provide comprehensive evidences on immunomodulatory role of the Trp catabolism metabolites that highlight this pathway as relevant target in immuno-oncology, ii)ii) discuss underwhelming results from clinical trials investigating efficacy of IDO1 inhibitors and underlying mechanisms that might have contributed to this failure, and finally, iii) discuss the current state-of-art surrounding alternative approaches of innovative antitumor immunotherapies that target molecules of Trp catabolism as well as challenges and perspectives in the era of immunotherapy.
Publisher
Frontiers Media SA,Frontiers,Frontiers Media S.A
Subject
/ Animals
/ Cancer
/ Enzyme Inhibitors - therapeutic use
/ Enzymes
/ Genes
/ Humans
/ Immunity
/ Indoleamine-Pyrrole 2,3,-Dioxygenase - antagonists & inhibitors
/ Indoleamine-Pyrrole 2,3,-Dioxygenase - metabolism
/ Kinases
/ Ligands
/ Melanoma
/ Oncology
/ Receptors, Aryl Hydrocarbon - metabolism
/ Tryptophan Oxygenase - antagonists & inhibitors
/ Tryptophan Oxygenase - metabolism
/ Tumors
